Skip to main content
Clinical Trials/NL-OMON51482
NL-OMON51482
Recruiting
Not Applicable

A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of PRAX-628 in Healthy Participants. - PRAX-628 in HV

Praxis Precision Medicines0 sites112 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Focal epilepsy
Sponsor
Praxis Precision Medicines
Enrollment
112
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Willing and able to provide informed consent indicating that they understand
  • the purpose of the clinical trial and the procedures that are required for the
  • clinical trial, and that they are willing to comply with scheduled visits, and
  • all studyrelated procedures.
  • 2\. Male or female between the ages of 18 and 55 years, inclusive.
  • 3\. Body mass index (BMI) of 18\.0 to 32\.0 kg/m2, inclusive, and a total body
  • weight of at least 50 kg.
  • 4\. Females of childbearing potential are not pregnant or breast\-feeding, have a
  • negative serum pregnancy test at Screening and a negative urine pregnancy test
  • at Baseline and are not planning to get pregnant for the duration of the trial.

Exclusion Criteria

  • 1\. Any clinically significant abnormalities, medical, or psychiatric conditions
  • identified by a detailed medical history, or physical examination, that in the
  • opinion of the investigator would pose an additional safety risk to the
  • participant or compromise the objectives of the study.
  • 2\. A history of cardiac disease(s)/cardiac conduction disorders/or cardiac
  • structural abnormality(ies) (e.g., atrial or ventricular septal defects,
  • valvular heart disease, coarctation of the aorta, or hypertrophic obstructive
  • cardiomyopathy).
  • 3\. Has a history of any lifetime suicide attempt or active suicidal ideation as
  • confirmed by C\-SSRS Baseline Version (Part B only).

Outcomes

Primary Outcomes

Not specified

Similar Trials